Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (12 quarters reported)
$236M in Q4 2020 → $24.6M now. Hover for any quarter.
As reported for the quarter ended September 30, 2023. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| VE Vaneck ETF Trust | 80.9% | Unchanged | 738,500 | $19.9M |
| Oric Pharmaceuticals Inc | 14.8% | Unchanged | 602,272 | $3.64M |
| Y-mabs Therapeutics Inc | 4.2% | Unchanged | 191,176 | $1.04M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2023 · filed November 14, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Caribou Biosciences Inc | Exited | −544,196 | −$2.31M | — |
| Illumina Inc | Exited | −6,187 | −$1.16M | — |
quarter ended June 30, 2023 · filed August 14, 2023
No position changes this quarter.
quarter ended March 31, 2023 · filed May 15, 2023
No position changes this quarter.
quarter ended December 31, 2022 · filed February 10, 2023
No position changes this quarter.
quarter ended September 30, 2022 · filed November 14, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Caribou Biosciences Inc | Trimmed | −65,000 | −$686K | 19.5% |
quarter ended June 30, 2022 · filed August 15, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Royalty Pharma PLC | Exited | −1,128,255 | −$44M | — |
| Caribou Biosciences Inc | Trimmed | −65,000 | −$353K | 10.9% |
| Illumina Inc | Trimmed | −700 | −$129K | 3.8% |
quarter ended March 31, 2022 · filed May 16, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Royalty Pharma PLC | Trimmed | −1,552,389 | −$60.5M | 50.9% |
| Illumina Inc | Trimmed | −10,309 | −$3.6M | 2.8% |
quarter ended December 31, 2021 · filed February 14, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Y-mabs Therapeutics Inc | Trimmed | −25,740 | −$417K | 1.9% |
Loading...
